Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Inclusion Criteria: * non-fertile women * primary symptomatic uterine descent POP-Q≥2 * Scheduled apical POP repair with Splentis * Willing and able to participate at study visits and to sign informed consent Exclusion Criteria: * Fertile women * Recurrent apical prolapse * Women with post hysterectomy vaginal vault prolapse * Patients with active or latent infection of the vagina, cervix or uterus * Patients with previous or current vaginal, cervical or uterine cancer * Previous, current or planned pelvic radiation therapy * Known allergy to polypropylene.